Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.

McGee HM, King MJ, Özbek U, Olson A, Kim E, Fischman AM, Schwartz M, Rosenzweig KE, Buckstein M.

Am J Clin Oncol. 2019 Apr;42(4):367-374. doi: 10.1097/COC.0000000000000523.

PMID:
30724782
2.

Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry.

Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, Mitsakis P, Silva-Monteiro M, Gnesin S, Lalonde MN, Duran R, Prior JO, Schaefer N.

J Nucl Med. 2017 Aug;58(8):1334-1340. doi: 10.2967/jnumed.116.184713. Epub 2017 Jan 12.

3.

Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.

Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V.

J Hepatol. 2018 Apr;68(4):724-732. doi: 10.1016/j.jhep.2017.12.026. Epub 2018 Jan 10.

4.

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.

Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group).

Liver Int. 2015 Mar;35(3):1036-47. doi: 10.1111/liv.12574. Epub 2014 May 20.

PMID:
24750853
5.

18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23.

PMID:
28233086
6.
7.

Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH.

Cardiovasc Intervent Radiol. 2018 Mar;41(3):459-465. doi: 10.1007/s00270-017-1826-7. Epub 2017 Oct 24.

PMID:
29067511
8.

Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.

Orwat KP, Beckham TH, Cooper SL, Ashenafi MS, Anderson MB, Guimaraes M, Yamada R, Marshall DT.

J Gastrointest Oncol. 2017 Dec;8(6):1072-1078. doi: 10.21037/jgo.2017.06.18.

9.

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Rognoni C, Ciani O, Sommariva S, Tarricone R.

Value Health. 2017 Mar;20(3):336-344. doi: 10.1016/j.jval.2016.09.2397. Epub 2016 Nov 4.

10.

Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.

She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM.

Hepatobiliary Surg Nutr. 2014 Aug;3(4):185-93. doi: 10.3978/j.issn.2304-3881.2014.07.09.

11.

Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.

Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N.

Oncotarget. 2017 Dec 19;9(4):4549-4558. doi: 10.18632/oncotarget.23423. eCollection 2018 Jan 12.

12.

In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF.

Liver Int. 2015 Feb;35(2):627-35. doi: 10.1111/liv.12637. Epub 2014 Aug 2.

PMID:
25040497
13.

Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):396-406. doi: 10.1016/j.ijrobp.2017.05.049. Epub 2017 Jun 6.

PMID:
28871990
14.

Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?

Cupino AC, Hair CD, Angle JF, Caldwell SH, Rich TA, Berg CL, Northup PG, Al-Osaimi AM, Argo CK.

Gastrointest Cancer Res. 2012 Jan;5(1):13-7.

15.

Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment.

Thayer D, Noda C, Charalel R, Mills A, Chang R, Tao Y, Akinwande O.

J Comp Eff Res. 2018 Apr;7(4):343-356. doi: 10.2217/cer-2017-0064. Epub 2018 Mar 19.

PMID:
29553286
16.

Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization.

Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE.

J Gastrointest Oncol. 2018 Jun;9(3):546-552. doi: 10.21037/jgo.2018.03.04.

17.

Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.

Cappelli A, Pettinato C, Golfieri R.

J Hepatocell Carcinoma. 2014 Nov 3;1:163-82. doi: 10.2147/JHC.S50472. eCollection 2014. Review.

18.

The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome.

Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, Chang JY.

Mol Biol Rep. 2012 Feb;39(2):2021-9. doi: 10.1007/s11033-011-0949-1. Epub 2011 Jun 7.

PMID:
21647551
19.

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.

Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.

Radiology. 2013 Nov;269(2):603-11. doi: 10.1148/radiol.13130150. Epub 2013 Jul 17.

PMID:
23864102
20.

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.

Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ.

Hepatology. 2018 Oct;68(4):1429-1440. doi: 10.1002/hep.29691. Epub 2018 Jan 29.

PMID:
29194711

Supplemental Content

Support Center